Alopexx
PublicAlopexx is now publicly traded
The data on this page reflects Alopexx's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jun 26, 2026
Last Round
Strategic
Sep 10, 2024
Total Funding Raised
$33M
Company Overview
Alopexx is a clinical-stage biotechnology company developing novel, broad-spectrum immune therapeutics for the prevention, treatment, and mitigation of bacterial, fungal, and parasitic infections.
AI Layer
Non-AI
Keywords
Alopexx Comparables
Compare Alopexx with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Trellis Bioscience | 77% | |
| Bioversys | 76% | |
| Aridis Pharmaceuticals, Inc. | 75% |
Alopexx Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Jun 26, 2026 | ||||
| Strategic | Sep 10, 2024 | ||||
| Strategic | Sep 6, 2024 |
Alopexx Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bharat Biotech | Strategic |
| ThinkEquity | IPO |
Alopexx Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access